Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy

由SARS-CoV-2引起的大流行在6个月的时间里已导致全球43万人死亡 总体而言，癌症患者感染后患重病和死亡的风险更高，尽管 不同的治疗方案是可能的(例如，化疗、免疫治疗和姑息治疗)。癌症患者 从新冠肺炎康复的人可能需要恢复治疗，包括对他们的疾病进行免疫治疗 尽管这种感染对他们的免疫系统的影响尚不清楚。这个项目将决定 如果从新冠肺炎康复的癌症患者具有与癌症不同功能的NK细胞 未感染的患者，以及这些表型是否对总应答率和 这群人的生存。

The pandemic caused by SARS-CoV-2 has killed 430,000 people worldwide in the span of 6 months which overall place cancer patients at a higher risk of severe illness and death if infected, although differences between distinct therapy regimens are possible (e.g. chemotherapy vs. immunotherapy vs. palliation). Cancer patients who have recovered from COVID-19 may need to resume treatment, including immunotherapy for their disease even though the repercussions of this infection on their immune systems are unknown. This project will determine if cancer patients who have recovered from COVID-19 have NK cells with different functionality than cancer patients who were not infected, and whether these phenotypes have an impact on the overall response rate and survival of this population.